VRTX · News · 20261113N
Product / Drug Pipeline Progress
VERTEX PHARMACEUTICALS INC / MA · 2026-11-13 · Importance 34 · Surprise 42
Vertex is awaiting an FDA decision on povetacicept for IgA nephropathy, scheduled for November 30. The decision could expand its commercial portfolio beyond cystic fibrosis. Early-2027 interim results from the AMPLITUDE trial of inaxaplin are another upcoming development, while the company’s JOURNAVX patient support program is being monitored.